Effect of rifampin (RIF) on the pharmacokinetics (PK) of atrasentan (ABT-627, ATN)

4728 Background: ATN, an oral endothelin antagonist with high selectivity for ETA receptor, is currently in phase 3 clinical development for the treatment of hormone-refractory prostate cancer. In ...